The role of megsin, a serine protease inhibitor, in diabetic mesangial matrix accumulation

20Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In diabetic nephropathy decreased activities of matrix metalloproteinase (MMP)-2, MMP-9 and plasmin contribute to mesangial matrix accumulation. Megsin, a novel member of the serine protease inhibitor superfamily, is predominantly expressed in mesangial cells and is up-regulated in diabetic nephropathy and its overexpression spontaneously induces progressive mesangial expansion in mice. High-glucose stimulated megsin mRNA expression in an in vivo model of type II diabetic nephropathy as well as in vitro in cultured mesangial cells. Megsin potentially inhibits total enzymatic activities of MMP-2 and -9 and plasmin, indicating decreased degradation of mesangial matrix. A specific monoclonal anti-megsin neutralizing antibody restored MMP activity in a transforming growth factor-β independent manner. Our study suggests that the mesangial matrix accumulation caused by hyperglycemia in diabetes might be due at least in part to up-regulation of megsin which can inhibit plasmin and MMP activities. © 2008 International Society of Nephrology.

Cite

CITATION STYLE

APA

Ohtomo, S., Nangaku, M., Izuhara, Y., Yamada, N., Dan, T., Mori, T., … Miyata, T. (2008). The role of megsin, a serine protease inhibitor, in diabetic mesangial matrix accumulation. Kidney International, 74(6), 768–774. https://doi.org/10.1038/ki.2008.302

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free